REVISIONS TO SIDE 2 REGARDING TRACK IV CASE TYPES
The Civil Case Information Statement (“Civil CIS”) is included in the Rules of Court as Appendix XII-B1. The Supreme Court previously delegated to the Administrative Director the authority to approve revisions to Side 2 of the Civil CIS. This Notice is to advise the bar of the approval of several such revisions to Side 2. The complete Civil CIS as revised is attached. No changes have been made to Side 1. The approved revisions, which are effective June 20, 2011, are as follows:
•
the addition of case type 293 for the DePuy ASR Hip Implant litigation, pursuant to the Supreme Court’s April 12, 2011 Order centralizing the management of the litigation but not designating it as a mass tort;
•
the addition of the term “Isotretinoin” to the description of case type 271, pursuant to the Supreme Court’s May 4, 2011 Order designating litigation involving Isotretinoin (generic Accutane) as part of the Accutane Litigation mass tort designation;
•
the removal of case type 275 for the Ortho Evra Birth Control Patch litigation, pursuant to the Supreme Court’s March 8, 2011 Order terminating mass tort designation and centralized management of the litigation;
•
the removal of case type 277 for the Mahwah Toxic Dump Site litigation, pursuant to the Supreme Court’s May 4, 2011 Order terminating mass tort designation and centralized management of the litigation; and
•
the removal of case type 283 for the Digitek litigation, pursuant to the Supreme Court’s May 17, 2011 Order terminating mass tort designation and centralized management of the litigation.
Appendix XII-B1
FOR USE BY CLERK’S OFFICE ONLY
Effective 06/20/2011, CN 10517-English page 1 of 2
PAYMENT TYPE: CK CG CA
CHG/CK NO.
AMOUNT:
OVERPAYMENT:
BATCH NUMBER:
CIVIL CASE INFORMATION STATEMENT
(CIS)
Use for initial Law Division
Civil Part pleadings (not motions) under Rule 4:5-1
Pleading will be rejected for filing, under Rule 1:5-6(c),
if information above the black bar is not completed
or attorney’s signature is not affixed
ATTORNEY / PRO SE NAME TELEPHONE NUMBER COUNTY OF VENUE
FIRM NAME (if applicable) DOCKET NUMBER (when available)
OFFICE ADDRESS DOCUMENT TYPE
JURY DEMAND YES NO
NAME OF PARTY (e.g., John Doe, Plaintiff) CAPTION
CASE TYPE NUMBER (See reverse side for listing) IS THIS A PROFESSIONAL MALPRACTICE CASE? YES NO
IF YOU HAVE CHECKED “YES,” SEE N.J.S.A. 2A:53 A -27 AND APPLICABLE CASE LAW
REGARDING YOUR OBLIGATION TO FILE AN AFFIDAVIT OF MERIT.
RELATED CASES PENDING? IF YES, LIST DOCKET NUMBERS
YES NO
DO YOU ANTICIPATE ADDING ANY PARTIES NAME OF DEFENDANT’S PRIMARY INSURANCE COMPANY (if known)
(arising out of same transaction or occurrence)? NONE
YES NO
UNKNOWN
THE INFORMATION PROVIDED ON THIS FORM CANNOT BE INTRODUCED INTO EVIDENCE.
CASE CHARACTERISTICS FOR PURPOSES OF DETERMINING IF CASE IS APPROPRIATE FOR MEDIATION
DO PARTIES HAVE A CURRENT, PAST OR IF YES, IS THAT RELATIONSHIP:
RECURRENT RELATIONSHIP? EMPLOYER/EMPLOYEE FRIEND/NEIGHBOR OTHER (explain)
YES NO FAMILIAL BUSINESS
DOES THE STATUTE GOVERNING THIS CASE PROVIDE FOR PAYMENT OF FEES BY THE LOSING PARTY? YES NO
USE THIS SPACE TO ALERT THE COURT TO ANY SPECIAL CASE CHARACTERISTICS THAT MAY WARRANT INDIVIDUAL MANAGEMENT OR
ACCELERATED DISPOSITION
DO YOU OR YOUR CLIENT NEED ANY DISABILITY ACCOMMODATIONS? IF YES, PLEASE IDENTIFY THE REQUESTED ACCOMMODATION
YES NO
WILL AN INTERPRETER BE NEEDED? IF YES, FOR WHAT LANGUAGE?
YES NO
I certify that confidential personal identifiers have been redacted from documents now submitted to the court, and will be
redacted from all documents submitted in the future in accordance with Rule 1:38-7(b).
ATTORNEY SIGNATURE:
Side 2
CIVIL CASE INFORMATION STATEMENT
(CIS)
Use for initial pleadings (not motions) under Rule 4:5-1
CASE TYPES (Choose one and enter number of case type in appropriate space on the reverse side.)
Track I - 150 days' discovery
151 NAME CHANGE
175 FORFEITURE
302 TENANCY
399 REAL PROPERTY (other than Tenancy, Contract, Condemnation, Complex Commercial or Construction)
502 BOOK ACCOUNT (debt collection matters only)
505 OTHER INSURANCE CLAIM (including declaratory judgment actions)
506 PIP COVERAGE
510 UM or UIM CLAIM (coverage issues only)
511 ACTION ON NEGOTIABLE INSTRUMENT
512 LEMON LAW
801 SUMMARY ACTION
802 OPEN PUBLIC RECORDS ACT (summary action)
999 OTHER (briefly describe nature of action)
Track II - 300 days' discovery
305 CONSTRUCTION
509 EMPLOYMENT (other than CEPA or LAD)
599 CONTRACT/COMMERCIAL TRANSACTION
603N AUTO NEGLIGENCE – PERSONAL INJURY (non-verbal threshold)
603Y AUTO NEGLIGENCE – PERSONAL INJURY (verbal threshold)
605 PERSONAL INJURY
610 AUTO NEGLIGENCE – PROPERTY DAMAGE
621 UM or UIM CLAIM (includes bodily injury)
699 TORT – OTHER
Track III - 450 days' discovery
005 CIVIL RIGHTS
301 CONDEMNATION
602 ASSAULT AND BATTERY
604 MEDICAL MALPRACTICE
606 PRODUCT LIABILITY
607 PROFESSIONAL MALPRACTICE
608 TOXIC TORT
609 DEFAMATION
616 WHISTLEBLOWER / CONSCIENTIOUS EMPLOYEE PROTECTION ACT (CEPA) CASES
617 INVERSE CONDEMNATION
618 LAW AGAINST DISCRIMINATION (LAD) CASES
Track IV - Active Case Management by Individual Judge / 450 days' discovery
156 ENVIRONMENTAL/ENVIRONMENTAL COVERAGE LITIGATION
303 MT. LAUREL
508 COMPLEX COMMERCIAL
513 COMPLEX CONSTRUCTION
514 INSURANCE FRAUD
620 FALSE CLAIMS ACT
701 ACTIONS IN LIEU OF PREROGATIVE WRITS
Centrally Managed Litigation (Track IV)
280 ZELNORM
290 POMPTON LAKES ENVIRONMENTAL LITIGATION
285 STRYKER TRIDENT HIP IMPLANTS
291 PELVIC MESH/GYNECARE
288 PRUDENTIAL TORT LITIGATION
292 PELVIC MESH/BARD
289 REGLAN
293 DEPUY ASR HIP IMPLANT LITIGATION
Mass Tort (Track IV)
248 CIBA GEIGY
281 BRISTOL-MYERS SQUIBB ENVIRONMENTAL
266 HORMONE REPLACEMENT THERAPY (HRT)
282 FOSAMAX
271 ACCUTANE/ISOTRETINOIN
284 NUVARING
274 RISPERDAL/SEROQUEL/ZYPREXA
286 LEVAQUIN
278 ZOMETA/AREDIA
287 YAZ/YASMIN/OCELLA
279 GADOLINIUM
601 ASBESTOS
If you believe this case requires a track other than that provided above, please indicate the reason on Side 1, in the space under "Case Characteristics.
Please check off each applicable category
Putative Class Action
Title 59
Effective 06/20/2011, CN 10517-English page 2 of 2
